Combination of Two Targeted Medications (Bevacizumab Plus Cetuximab) Improve the Therapeutic Response of Pancreatic Carcinoma.

Medicine (Baltimore) · 2016 · PMC4839806 · PMID 27082562

Europe PMC DOI

hedged sentence

0.1500

closest p · 3.0× alpha

0.1500

boldest claim

The sentences

did not reach statistical significanceP = 0.15not close (p > 0.1)

41.9%, respectively); however, this did not reach statistical significance ( P = 0.15).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.